|
|
CME
Urinary incontinence
Non-surgical management by family physicians
K.N. Moore, RN, PHD A. Saltmarche B.
Query
ABSTRACT
OBJECTIVE
To review current evidence on conservative management of urinary incontinence
(UI) by family physicians.
QUALITY OF EVIDENCE
Articles were sought through MEDLINE, EMBASE, Cochrane Database of Systematic
Reviews, CINAHL, PsycLit, ERIC, two consensus meetings, and review of
abstracts presented at urology meetings. References of these articles
were searched for relevant trials. Strong evidence supports bladder training,
pelvic floor exercises, and some medications, but only fair evidence supports
fluid adjustment, caffeine reduction, and stopping smoking. Weight loss
and exercise are supported by expert opinion only. Consensus opinion is
that, whenever possible, conservative management should be considered
first.
MAIN MESSAGE
Good evidence shows that initial management by primary care physicians
is effective. After basic assessment and tests, strategies such as bladder
retraining, pelvic floor exercises, and lifestyle modifications, augmented
by appropriate medications, can be successful. If initial strategies are
unsuccessful, patients can be referred.
CONCLUSION
More than a million Canadians suffer from UI. In almost all cases, family
physicians are the first health professionals contacted by patients. Basic
assessment and conservative management can go far to ameliorate the problem.
RÉSUMÉ
OBJECTIF
Passer en revue les données actuelles sur le rôle du médecin de famille
dans le traitement conservateur de l’incontinence urinaire (IU).
QUALITÉ DES PREUVES
On a utilisé MEDLINE, EMBASE, Cochrane Database of Systematic Reviews,
CINAHL, PsycLit, ERIC, deux congrès de consensus et l’examen des résumés
de communications d’un congrès d’urologie comme sources de données. Les
références bibliographiques des articles retenus ont été examinées pour
identifier les essais thérapeutiques pertinents. Les méthodes fondées
sur des preuves solides incluent la rééducation vésicale, le renforcement
du plancher pelvien et certaines médications; par contre, l’ajustement
des liquides, la réduction de la caféine et l’arrêt du tabac sont moins
bien appuyés scientifiquement. La réduction du poids et l’exercice sont
recommandés seulement par les experts. Le consensus général est qu’ on
doit débuter par un traitement conservateur chaque fois que possible.
PRINCIPAL MESSAGE
Les données montrent clairement que le médecin de première ligne peut
effectuer le traitement initial efficacement. Après l’évaluation et les
examens de base, des méthodes comme la rééducation vésicale, le renforcement
des muscles du plancher pelvien et les modifications du mode de vie peuvent
avoir du succès. En cas d’échec de ces stratégies, le patient peut être
dirigé en spécialité.
CONCLUSION
Plus d’un million de canadiens souffrent d’IU. Dans presque tous les cas,
le médecin de famille est le premier professionnel de santé consulté.
Une évaluation de base et un traitement conservateur peuvent faire beaucoup
pour améliorer ce problème.
This article has been peer reviewed. Cet article
a fait l’objet d’une évaluation externe.
Can Fam Physician 2003;49:602-610.
Ms Moore is an Assistant Professor
in the Faculty of Nursing and an Adjunct Professor in the Faculty of Medicine
at the University of Alberta in Edmonton. Ms Saltmarche
and Ms Query are nurses.
A national Angus Reid poll noted that 1.5 million
Canadians (7%) had suffered from urine loss in the previous year and that
the prevalence increased with age to 12% of women and 2.5% of men older
than 55. At least 16% of seniors living at home need assistance for urinary
incontinence (UI).1 People with UI report
restrictions on physical activity,2,3
stress, frustration, thoughts of suicide,4
confusion, depression, anger, less well-being,5
low self-esteem, social isolation, and poor sleep.6,7
Family physicians are the first contact for most people with UI; initial
assessment and intervention for UI by family physicians is effective and
long lasting.8-10
Despite the prevalence of UI and the fact that family
physicians are the first point of entry, recent graduates of family practice
residency training in Ontario stated they received inadequate training
in assessment and management of UI.11
In this paper, we review available evidence and describe initial assessment
and conservative management of UI. Conservative management in this article
means lifestyle adjustments and pelvic floor muscle exercises (PFME) with
or without medications.
Quality of evidence
The Cochrane Database, MEDLINE, CINAHL, EMBASE, PsycLit,
and ERIC were searched from January 1995 to January 2001. Because an authoritative
literature review was done in 1994,12
we chose 1995 as the start date for our search. We used the search terms
incontinence, electrical stimulation, biofeedback, pelvic muscle/Kegel
exercises, behaviour/modification, conservative, physiotherapy, and quality
of life. Consensus documents,12-16 conference
proceedings, and all reference lists of articles retrieved were consulted.
Levels of evidence follow the recommendations of the Canadian Medical
Association.17
Classification of UI
At presentation, UI is classified by symptoms. Cause
is presumed rather than confirmed and is described as urge (or overactive
bladder), stress, mixed urge and stress, or retention with overflow. Definitive
diagnosis requires a detailed, expert assessment, usually including urodynamics.
Because the bladder can be an “unreliable witness,”18,19
if initial strategies are ineffective, referral to a specialist is indicated.
Table 1 summarizes symptoms, presumed cause, and usual
treatment strategies at the primary care level.
Assessment
A plan for initial assessment of patients with UI was
recently suggested.20 It emphasized sensitive
questioning about the effect of UI on daily life; detailed history; focused
pelvic, rectal, and neurologic examinations; urinalysis (microscopy or
dipstick); using a voiding diary; and assessing postvoid residual (PVR)
volume, if indicated (Table 220).
Although most guidelines for UI recommend initial PVR testing,12
the value in family practice has only recently been investigated. In a
study of 408 women who came to an incontinence clinic for initial assessment,
only six had clinically significant residual urine; the authors concluded
that a PVR test is unnecessary in primary assessment of women with UI.21
Vaginal or rectal examination can be used to assess
pelvic floor muscle tone, sensation, contractile ability, and atrophic
changes. A fluid volume chart (voiding diary, Figure 1)
is easy for most patients to complete22
and can be used to assess voiding patterns and fluid intake over 1 to
3 days. A voiding diary can reliably discriminate between urge and stress
UI23: patients with stress UI usually
wake once or not at all to void; patients with urge UI usually wake more
than twice and as often as every hour. A dietary and stool record is helpful
if constipation or fecal soiling are problems.
Several transient problems exacerbate UI: urinary tract
infections, constipation, dementia or delirium, atrophic vaginitis, and
medications. Medications that most frequently cause problems are -blockers,
which relax the smooth muscle of the bladder neck and worsen stress UI.24
In at-risk patients, angiotensin-converting enzyme inhibitors can cause
a dry cough that also exacerbates stress UI.25
Finally, hypnotics, some antipsychotics, narcotics, and anticholinergics
put people at risk of urinary retention. Patients who develop UI after
a medication change should be reviewed for side effects.
Conservative management
Conservative management (also called behavioural strategies
or lifestyle adjustments) is noninvasive and includes PFMEs, bladder training,
fluid adjustment, caffeine elimination, smoking cessation, bowel management,
weight reduction, and physical exercise. Experts suggest that most people
will benefit from and should be offered behavioural strategies as first-line
treatment.12-16
|
| PRESUMED CAUSE |
DESCRIPTION |
TREATMENTS OFFERED THROUGH PRIMARY
CARE |
| Overactive bladder, urge incontinence |
Loss of urine associated with a strong
desire to void; might be accompanied by frequency and nocturia; nocturia
is typically described by patients with overactive bladder but not
by those with stress UI |
Bladder training, timed toileting, fluid
management, medication review Constipation management
PFME and PFME with biofeedback
Electrical stimulation (10-20 Hz) Estrogen therapy
Anticholinergic or antimuscarinic medications
Incontinence pads Environmental modifications, such as bedside commodes,
night lights, and clearly marked toilets |
| Stress UI |
Loss of urine on physical exertion or
increases in abdominal pressure due to laughing, coughing, or sneezing,
or due to sphincter deficiency; patients with stress UI are usually
dry at night and do not complain of nocturia |
Weight loss
Fluid increase or decrease Smoking cessation
Constipation management PFME and PFME with biofeedback
Pessary (occasionally)
Incontinence pads |
| Mixed UI (overactive bladder and stress
UI) |
Loss of urine with both urge and increases
in abdominal stress; symptoms are mixed with urgency, frequency, nocturia,
and leaking with increased abdominal pressures |
Combination of above conservative measures
with an initial focus on dominant symptom |
| Overflow |
Leakage associated with bladder distension
or urinary retention; leakage with increased abdominal pressure; might
be confused with stress UI; due to a contractile or poorly contractile
detrusor or outlet obstruction; chronic retention is usually painless |
Refer
Clean intermittent catheterization
Relief of obstruction (in women, cystocele, uterine prolapse, tumour;
in men, prostatic enlargement hyperplasia, urethral stricture, bladder
tumour)
Medication review
-Blockers
Last resort: indwelling catheter |
| PFME—pelvic floor muscle
exercises, UI—urinary incontinence. |
|
| INVESTIGATION |
DESCRIPTION |
| Focused neurologic examination |
General assessment of sacral (S2-5)
dermatomes: evaluates perineal and saddle sensation, rectal tone and
sensation, and ability of rectal sphincter to remain contracted with
stimulus of digital examination; abnormalities suggest some neurologic
impairment and possibly referral to a neurologist |
| Rectal or vaginal examination |
Rectal examination will reveal prostate
enlargement, stool impaction (which might affect continence), and
rectal tone and sensation (above); vaginal examination will reveal
atrophic vaginitis, cystocele, uterine prolapse, rectocele, and pelvic
floor tone when patient coughs or strains. A rectocele does not cause
urinary incontinence; however, stool can collect in the rectocele
and might need to be evacuated manually or by placing a finger in
the vagina or on the perineum to provide resistance while defecating.
Such maneuvers can be embarrassing. Referral to a gynecologist or
urogynecologist is indicated if methods to reduce stool pocketing,
such as stool softeners, fibre, and lubricants, are ineffective |
| Postvoid residual test with ultrasound
scan or in-out catheterization (generally >150 mL is considered
significant, but treatment should be based on symptoms rather than
PVR volume alone)20 |
Recommended if symptoms suggest incomplete
emptying typically described as straining to void, intermittent stream
or hesitancy, and for some, never feeling empty or leaking with increased
abdominal pressure Physical examination might reveal distended bladder
but abdominal palpation might be accurate only when bladder is grossly
distended Patients at risk for incomplete emptying are those with
neurologic diseases (eg, multiple sclerosis), history of urethral
strictures, peripheral neuropathies (diabetes, alcohol abuse, B12
deficiency), or medications with anticholinergic properties. Women
with uterine prolapse or marked cystocele and men with prostatic hyperplasia
are at risk. Patients with symptoms and PVR volume can be managed
initially with -blockers
or intermittent catheterization. Referral to a urologist is indicated
if symptoms persist. |
| PVR—postvoid residual.
For more strategies, see Borrie and Valiquette.20 |

Pelvic floor muscle exercises.
Exercises should increase awareness of pelvic muscle function and increase
the strength and endurance of voluntary muscles. The benefits to women
without prolapse who follow an intensive exercise regimen are well known26-29
and long lasting.30,31 Primiparous women
who practise PFME have fewer episodes of UI during pregnancy and afterward
than controls.32 The benefits of PFMEs
in men after radical prostatectomy are not as clear. In a Cochrane review
of six randomized controlled trials,33
only one showed a significant effect of postprostatectomy exercises. Although
further research is required, the reviewers concluded that PFMEs after
radical prostatectomy might enhance continence recovery and had several
quality-of-life benefits, and that men should not be discouraged from
participating in programs should they wish to do so.
Exercises are most effectively taught with vaginal
or rectal palpation to help patients identify the correct muscles and
timing of contractions. Men should see the base of the penis, pull up
and in. Without adequate instruction, between 30% and 70% of patients
cannot perform effective PFMEs.34 Figure
2 shows the PFME illustrations provided by the Canadian Continence
Foundation (www.continence-fdn.ca). This basic information is best combined
with teaching, support, and ongoing follow up by a physiotherapist or
nurse (level I evidence). Augmenting PFMEs with biofeedback or electrical
stimulation35,36 might increase the effectiveness
of therapy (level II evidence).

Bladder training. Bladder
training (also called urge suppression or scheduled voiding) is an important
first-line strategy.37 The intent is
to increase the voiding interval by consciously suppressing the urge to
void; patient education, scheduled voiding, positive reinforcement, and
ongoing support are helpful.12 Keys to
success are good sensation of bladder fullness, adequate pelvic muscle
tone (assessed by a pelvic examination), motivation, and cognitive ability.
Adding other behavioural methods or short-term anticholinergics38
might increase effectiveness. A recent Cochrane review on bladder training
identified seven randomized controlled trials39
that noted improvement in subjects who had participated in bladder training
compared with no treatment or no bladder training (level I evidence).
Table 3 outlines a bladder-training protocol.
Fluid adjustment and caffeine reduction.
Controlled fluid reduction, such as restricting fluids in the evening,
and nighttime toileting might reduce UI symptoms in elderly people.40
If fluid intake is low (less than 30 mL/kg), however, increased fluid
intake might improve symptoms.41 Physiologic
evidence suggests that caffeine precipitates symptoms of UI,42
but clinical evidence of the effectiveness of caffeine reduction is unclear.43,44
In one study, subjects randomly assigned to ingest no caffeine at all
had significantly fewer episodes of incontinence (as recorded by bladder
diary) than controls45 (level II evidence).
Reducing or stopping of cigarette smoking.
Smoking is a risk factor for UI in women older than 60 who have chronic
obstructive pulmonary disease and chronic respiratory symptoms46,47;
in younger women, the relationship is less clear.48
Chronic coughing might cause gradual anatomic and pressure transmission
defects that could contribute to stress UI.49
A retrospective case-control study of women who never smoked and women
who currently smoked showed that the relative risk of urge or stress incontinence
increased by 2.2 for women who previously smoked and by 2.5 for those
who currently smoked. Risk increased with number of cigarettes and years
as a smoker.50
Men aged 50 to 70 who smoke or are former smokers have
an increased risk of lower urinary tract symptoms (odds ratio 1.47 and
1.38, respectively) compared with those who never smoked.51
No studies were found that measured the effect of smoking cessation on
immediate improvement in lower urinary tract symptoms or continence (level
II evidence).
Weight reduction. Obesity
is a known risk factor for UI in women and is independent of obstetric
history, surgery, smoking, and family history.52
Defined as greater than 120% of the average weight for height and age,
obesity is significantly more prevalent in women with stress UI and overactive
bladder than in the general population.53
Women with profound weight loss after bypass surgery report a marked improvement
in stress UI.54 Results of more modest
weight-loss programs are not reported13
(level II evidence for profound weight loss, level III evidence for modest
weight loss).
|
| 1. Establish a voiding pattern by using
a bladder diary (fluid volume chart) to record number and volume of
voids, incontinence episodes, and fluid intake. |
| 2. Determine a voiding interval based
on the voiding pattern. If frequency is more than every 60 minutes,
void every 60 minutes; if less than 60 minutes, start with 30-minute
intervals. After 2 days without incontinence, increase time between
voids by 30 minutes. Continue this process until voiding every 3 to
4 hours. |
| 3. Teach urge suppression. Pelvic muscle
exercises and distraction techniques can help dissipate the urge to
void. To control the urge, take a deep breath and relax. Stand still
or sit down. Contract your pelvic floor muscles five or six times.
Count backward from 100. Concentrate on having the urge decrease.
Wait until it passes, and then resume your activities. If it is longer
than 2 hours since last void, proceed slowly to the toilet to empty
your bladder. Rushing to the toilet will make symptoms of urgency
much worse. |
| 4. Gradually increase length of time
between voids as continence is achieved. |
| 5. Record progress on fluid volume chart
or bladder diary. A daily or weekly bladder diary helps to track progress. |
| 6. Follow up regularly. Bladder retraining
requires a lot of work and commitment. Encouragement is important
for success. Successful bladder retraining can take several weeks. |
Bowel management. Growing
evidence links UI, constipation, fecal incontinence, and pelvic organ
prolapse with each other and each of these conditions, in turn, to pelvic
floor denervation, pudendal neuropathy, and progressive chronic dysfunction.55-57
Constipation can cause bladder neck obstruction and obstructive voiding58;
fecal incontinence can cause social isolation far beyond that of UI and
remains a taboo topic.59 Referral is
required if initial dietary and nonstimulant bowel preparations are ineffective
in ameliorating constipation or fecal incontinence (level III evidence).
Physical activity and regular exercise.
Men aged 40 to 75 who undertake moderate exercise (walking
2 to 3 hours weekly) have a 25% lower risk of benign prostatic hyperplasia
than men who do not exercise,60 but there
are no similar studies in women. People limit their activities or stop
exercising because of UI, thereby increasing the risk of other weight-related
problems (level III evidence).
Medications
Table 4 describes medications commonly
prescribed for UI. Good evidence shows that treatment with the anticholinergic
medications oxybutynin and tolterodine results in increased bladder capacity,
increased time between urge to void, and delayed initial desire to void.61
Oxybutynin as low as 2.5 mg at bedtime is effective, particularly for
elderly patients. Increasing the dose gradually by 2.5 mg until tolerance
is reached reduces side effects and increases the likelihood that patients
will continue the medication. Side effects are the main reason for discontinuing
the drug, particularly xerostomia, which places patients at risk of dental
caries; mouth moisturizers plus regular dental care are important. Tolterodine
is consistently reported to have fewer side effects than oral oxybutynin.62
Both oxybutynin and tolterodine extended-release formats are reported
to have fewer side effects with once-a-day dosing (level I evidence).
|
CLAS-
SIFICA-
TION |
GENERIC DRUG NAME |
MECHANISM OF ACTION |
CONTRA-
INDICA-
TIONS |
DOSE AND HALF-LIFE |
SIDE EFFECTS |
nti-cholinergics
and anti-
muscarinics (level I evidence) |
Oxybutynin Oxybutynin XL |
Antispasmodic and
slight analgesic effect on smooth muscle; inhibits acetylcholine effects
on smooth muscle All are metabolized primarily by cytochrome P-450-3A4 |
As for all anticholinergic
medications: narrow-angle glaucoma; gastrointestinal obstruction or
atony; ulcerative colitis, myasthenia gravis; urinary retention or
PVR volume (can be used in conjunction with intermittent catheterization) |
2.5-5 mg one to four times
daily; half-life elimination 1-3 h; time to peak 60 min; onset 30-60
min, peak effect 3-6 h; lipophilic, crosses blood-brain barrier Oxybutynin
XL takes 4-6 hrs to reach peak; steady state achieved in about 3 days;
available in 5 and 10 mg |
Constipation, dry mucosa
(mouth, vagina, eyes); in elderly people, confusion, decreased cognition
(drug crosses blood-brain barrier); blurred vision; can result in
urinary retention. At-risk patients should be monitored for PVR volume
(Table 2). Note: gradually increasing oral dose increases
tolerance, especially among elderly people; doses as low as 2.5 mg
at bedtime are effective for some elderly patients.
Warn patients that the empty capsule from oxybutynin LA will be excreted
in the feces |
|
Tolterodine Tolterodine
LA |
More selective on M3 receptors
than oxybutynin, resulting in fewer anticholinergic side effects |
As above, but adjust dosage
if concurrent use of cytochrome P-450-3A4 inhibitors (fluoxetine increases
concentration 4.8 times) |
1-2 mg twice daily; could
take up to 8 wk to reach optimum benefit; tolterodine LA 4 mg |
As above but less because
of selectivity of M3 bladder receptors over salivary receptors |
| Tricyclic anti-depressants (level II
evidence) |
Imipramine, doxepin, desipramine, nortriptyline |
|
Decrease in nocturnal incontinence;
side effects common |
25 mg at bedtime; up to 25 mg three
times daily
Half-life 6-18 h |
As above; occasional orthostatic hypotension |
| Hormone replacement
therapy (level I evidence) |
Conjugated estrogen vaginal
cream
Slow-release estradiol ring |
Reduces irritation from
atrophic vaginitis
Note: Dose is too low to provide systemic benefits of estrogen therapy |
Generally contraindicated
in women with history of endometrial, ovarian, or breast cancer |
Cream: 1-2 g at bedtime
for 2 wk, then twice weekly at bedtime Estradiol ring: change every
3 mo |
Might cause sore breasts
or spotting; must be applied intravaginally, not on labia |
| M3—muscarinie, PVR—postvoid
residual. |
Finally, local treatment of urogenital atrophy with
low-dose estrogen appears to have clinical benefit for postmenopausal
women experiencing urgency, urge UI, vaginal dryness, and dyspareunia.
A recent Cochrane review63 showed that
women with symptoms of overactive bladder had marked improvement in nocturia,
urgency, and daytime frequency, but little benefit was found for women
with stress UI. Doses and administration varied in the studies, but topical,
intermittent estrogen or sustained-release estradiol appeared to be as
effective as oral or patch medication in relieving symptoms. Excessive
use of topical creams can result in systemic effects, but when used as
directed, effects are minimal. In low doses, the additional systemic benefits
of estrogens are probably minimal, but because of the low dose, endometrial
stimulation is unlikely, and progestin protection is seldom necessary
(level I evidence for relief of urge symptoms).
Conclusion
Urinary incontinence is a common health problem that
seriously affects patients’ lives. Although family physicians are often
patients’ first contact, physicians feel unprepared to address the issue
of UI, and both parties feel disappointed. Consensus opinion and clinical
trials suggest that conservative management is safe, effective, and can
be offered through primary care. Referral is indicated if symptoms do
not resolve with initial interventions or if symptoms suggest underlying
urologic or gynecologic problems. The best available evidence supports
family physicians as pivotal in identifying patients with UI, initiating
discussion, beginning assessment, and implementing basic management strategies.
Competing interests
None declared
Correspondence to: Katherine
N. Moore, Assistant Professor Faculty of Nursing, Faculty of Medicine,
3rd floor, Clinical Sciences Building, University of Alberta, Edmonton,
AB T6G 2G3; telephone (780) 482-1541; fax (780) 482-2551; e-mail
katherine.moore@ualberta.ca
References
1. Angus Reid poll. Urinary incontinence in the Canadian
adult population. Survey commissioned by the Canadian Continence Foundation.
Toronto, Ont: Angus Reid Group; 1997.
2. Herr H. Quality of life in incontinent men after radical prostatectomy.
J Urol 1994;151:652-4.
3. Jonler M, Madsen FA, Rhodes PR, Sall M, Messing EM, Bruskewitz RC.
A prospective study of quantification of urinary incontinence and quality
of life in patients undergoing radical retropubic prostatectomy. Urology
1996;48:433-40.
4. Moore KN, Estey A. The early post-operative concerns of men after radical
prostatectomy. J Adv Nurs 1999;29:1121-9.
5. Chiverton PA, Wells TJ, Brink CA, Mayer R. Psychological factors associated
with urinary incontinence. Clin Nurse Spec 1996;10:229-33.
6. Grimby A, Milsom I, Molander U, Wiklund I, Ekelund P. The influence
of urinary incontinence on the quality of life of elderly women. Age Ageing
1993;22:82-9.
7. Hunskaar S, Visnes A. The quality of life in women with urinary incontinence
as measured by the Sickness Impact Profile. J Am Geriatr Soc 1991;39:378-82.
8. Lagro-Janssen AL, Debruyne FM, Smits AJ, van Weel C. The effects of
treatment of urinary incontinence in general practice. Fam Pract 1992;9:284-9.
9. Lagro-Janssen AL, van Weel C. Long-term effect of treatment of female
incontinence in general practice. Br J Gen Pract 1998;48:1735-8.
10. Seim A, Hermstad R, Hunskaar S. Management in general practice significantly
reduced psychosocial consequences of female urinary incontinence. Qual
Life Res 1997;6:257-64.
11. Shultz JA, Klag M, Drutz HP. A survey of Canadian family physician
training in pelvic floor dysfunction [abstract]. Int Urogynecol J 2000;11(Suppl
1):S78.
12. Agency for Health Care Policy and Research. Urinary incontinence in
adults: acute and chronic management. A clinical practice guideline. Update.
Rockville, Md: US Department of Health and Human Services; 1996. Publication
96-0862.
13. Wilson PD, Bø K, Bourcier A, Hay-Smith J, Staskin D, Nygaard I, et
al. Conservative management in women. In: Abrams P, Khoury S, Wein A,
editors. Incontinence: 1st International
Consultation on Incontinence, Monaco, 1998. Plymouth, Engl: Plymbridge
Distributors Ltd; 1999. p. 581-636.
14. Canadian Continence Foundation. Canadian Continence Foundation consensus
conference on clinical practice guidelines and models for delivery of
continence care in Canada. Sponsored by the Canadian Continence Foundation.
Montreal, Que; May 2000. Available at: http://continence-fdn.ca.
Accessed 2003 February 11.
15. Bø K, Stien R, Kulseng-Hanssen S, Kristofferson M. NIH Consensus Development
Panel: urinary incontinence in adults. JAMA 1989;261:2685-90.
16. Wilson PD, Bo K, Boureier A, Hay-Smith J, Staskin D, Nygaard I, et
al. Conservative management in women. In: Abrams P, Khoury S, Wein A,
editors. Incontinence: 1st International
Consultation on Incontinence, Monaco, 1998. Plymouth, Engl: Plymbridge
Distributors Ltd; 1999. p. 579-636.
17. Patterson CJ, Gauthier S, Bergman H, Cohen CA, Feightner JW, Felman
H, et al. The recognition, assessment and management of dementing disorders:
conclusions from the Canadian Consensus Conference on Dementia. Can Med
Assoc J 1999;160(2 Suppl):S1-15.
18. Blaivas JG. The bladder is an unreliable witness. Neurourol Urodyn
1996;15:443-5.
19. Ding YY, Lieu PK, Choo PW. Is the bladder “an unreliable witness”
in elderly males with persistent lower urinary tract symptoms? Geriatr
Nephrol Urol 1997;7:17-21.
20. Borrie MJ, Valiquette L. Managing adults with urinary incontinence.
Clinical practice guidelines. Can Fam Physician 2002;48:114-6.
21. Sander P, Mouritsen L, Thorup-Andersen J, Fischer-Rasmussen W. Should
measurement of maximum urinary flow rate and residual urine volume be
a part of a ‘minimal care’ assessment program in female incontinence?
Scand J Urol Nephrol 2002;36:124-7.
22. Robinson D, McClish DK, Wyman JF, Bump RC, Fantl JA. Comparison between
urinary diaries completed with and without intensive patient instructions.
Neurourol Urodyn 1996;15:143-8.
23. Fink D, Perucchini D, Scherj GN, Haller U. The role of the frequency-volume
chart in the differential diagnostic of female urinary incontinence. Acta
Obstet Gynecol Scand 1999;78:254-7.
24. Marshall HJ, Beevers DG. Alpha-adrenoceptor blocking drugs and female
urinary incontinence: prevalence and reversibility. Br J Clin Pharmacol
1996;42:1507-9.
25. Menefee SA, Chesson R, Wall LL. Stress urinary incontinence due to
prescription medications: alpha-blockers and angiotensin converting enzyme
inhibitors. Obstet Gynecol 1998;91:853-4.
26. Bø K, Talseth T, Holme I. Single blind randomized controlled trial
of pelvic floor exercises, electrical stimulation, vaginal cones or no
treatment in management of genuine stress incontinence in women. BMJ 1999;318:487-93.
27. Sampselle C, Wyman J, Thomas K, Newman D, Gray M, Dougherty M, et
al. Continence for women: evaluation of AWHONN’s evidence-based protocol.
J Obstet Gynecol Neonat Nurs 2000;29:18-26.
28. Wyman J, Fantl A, McClish D, Bump R. Comparative efficacy of behavioral
interventions in the management of female urinary incontinence. Am J Obstet
Gynecol 1998;179:999-1007.
29. Miller J, Aston-Miller J, Delancey J. A pelvic muscle precontraction
can reduce cough-related urine loss in selected women with mild SUI. J
Am Geriatr Soc 1998;46:870-4.
30. Bø K, Talseth T. Long-term effect of pelvic floor muscle exercise
5 years after cessation of organized training. Obstet Gynecol 1996;87:261-5.
31. O’Brien J. Evaluating primary care interventions for incontinence.
Nurs Stand 1996;10:40-3.
32. Laycock J. Clinical evaluation of the pelvic floor. In: Sch ssler
B, Laycock J, Norton P, Stanton S, editors. Pelvic floor re-education:
principles and practice. London, Engl: Springer-Verlag; 1994. p. 42-8.
33. Moore KN, Cody DJ, Glazener CM. Conservative management of post prostatectomy
incontinence (Cochrane Review). In: The Cochrane Library [database on
disk and CD-ROM]. Issue 1. Oxford, Engl: Update Software; 2002.
34. Bø K, Larson S, Oseid S, Kvarstein B, Hagen R, Jørgensen J. Knowledge
about and ability to correct pelvic floor muscle exercises in women with
urinary stress incontinence. Neurourol Urodyn 1988;7:261-2.
35. Bø K. Vaginal weight cones. Theoretical framework, effect on pelvic
floor muscle strength and female stress urinary incontinence. Acta Obstet
Gynecol Scand 1995;74:87-92.
36. Herbison P, Plevnik S, Mantle J. Weighted vaginal cones for urinary
incontinence (Cochrane Review). In: The Cochrane Library [database on
disk and CD-ROM]. Issue 2. Oxford, Engl: Update Software; 2000.
37. Wyman JF, Fantl JA. Bladder training in ambulatory care management
of urinary incontinence. Urol Nurs 1991;11:11-7.
38. Szonyi G, Collas DM, Ding YY, Malone-Lee JG. Oxybutynin with bladder
retraining for detrusor instability in elderly people: a randomized controlled
trial. Age Ageing 1995;24:287-91.
39. Roe B, Williams K, Palmer M. Bladder training for urinary incontinence
in adults (Cochrane Review). In: The Cochrane Library [database on disk
and CD-ROM]. Issue 4. Oxford, Engl: Update Software; 1999.
40. Griffiths DJ, McCracken PN, Harrison GM, Gormley EA. Relationship
of fluid intake to voluntary micturition and urinary incontinence in geriatric
patients. Neurourol Urodyn 1993;12:1-7.
41. Dowd TT, Campbell JM, Jones JA. Fluid intake and urinary incontinence
in older community-dwelling women. J Community Health Nurs 1996;13:179-86.
42. Creighton SM, Stanton SL. Caffeine: does it affect your bladder? Br
J Urol 1990;66:613-4.
43. Tomlinson BU, Dougherty MC, Pendergast JF, Boyington AR, Coffman MA,
Pickens SM. Dietary caffeine, fluid intake and urinary incontinence in
older rural women. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:22-8.
44. Fried GW, Goetz G, Potts-Nulty S, Cioschi HM, Staas WE Jr. A behavioral
approach to the treatment of urinary incontinence in a disabled population.
Arch Phys Med Rehabil 1995;76:1120-4.
45. Bryant CM, Dowell CJ, Fairbrother G. A randomised trial of the effects
of caffeine upon frequency, urgency and urge incontinence. Neurourol Urodyn
2000;19:501-2.
46. Diokno AC, Brock BM, Herzog AR, Bromberg J. Medical correlates of
urinary incontinence in the elderly. Urology 1990;36:129-38.
47. Brown JS, Seeley DG, Fong J, Black DM, Ensrud KE, Grady D. Urinary
incontinence in older women: who is at risk? Study of the Osteoporotic
Fractures Research Group. Obstet Gynecol 1996;87:715-21.
48. Burgio KL, Matthews KA, Engel BT. Prevalence, incidence and correlates
of urinary incontinence in healthy, middle-aged women. J Urol 1991;146:1255-9.
49. Bump RC, McClish DK. Cigarette smoking and pure genuine stress incontinence
of urine: a comparison of risk factors and determinants between smokers
and nonsmokers. Am J Obstet Gynecol 1994;170:579-82.
50. Bump RC, McClish DK. Cigarette smoking and urinary incontinence in
women. Am J Obstet Gynecol 1992;167:1213-8.
51. Koskimaki J, Hakama M, Huhtala H, Tammela TL. Association of smoking
with lower urinary tract symptoms. J Urol 1998;159:1580-2.
52. Wingate L, Wingate MB, Hassanein R. The relation between overweight
and urinary incontinence in postmenopausal women: a case control study.
J North Am Menopaus Soc 1994;1:199-203.
53. Dwyer PL, Lee ETC, Hay DM. Obesity and urinary incontinence in women.
Br J Obstet Gynaecol 1988;95:91-6.
54. Bump RC, Sugerman HJ, Fantl JA, McClish DK. Obesity and lower urinary
tract function in women: effect of surgically induced weight loss. Am
J Obstet Gynecol 1992;167:392-9.
55. Jackson SL, Weber AM, Hull TL, Mitchinson AR, Walters MD. Fecal incontinence
in women with urinary incontinence and pelvic organ prolapse. Obstet Gynecol
1997;89:423-7.
56. Pannek J, Haupt G, Sommerfeld HJ, Schulze H, Senge T. Urodynamic and
rectomanometric findings in urinary incontinence. Scand J Urol Nephrol
1996;30:457-60.
57. Smith AR, Hosker GL, Warrell DW. The role of pudendal nerve damage
in the aetiology of genuine stress incontinence in women. Br J Obstet
Gynaecol 1989;96:29-32.
58. MacDonald A, Shearer M, Paterson PJ, Finlay IG. Relationship between
outlet obstruction constipation and obstructed urinary flow. Br J Surg
1991;78:693-5.
59. Saltmarche A, Reid DW, Linton L. Rural continence management project.
Research report submitted to the Assistive Devices Program, Ontario Ministry
of Health. Toronto, Ont: Ontario Ministry of Health; 1992.
60. Platz EA, Kawachi I, Rimm EB, Colditz GA, Stampfer JF, Willett WC,
et al. Physical activity and benign prostatic hyperplasia. Arch Intern
Med 1998;158:2349-56.
61. Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the
treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol
2001;185:56-61.
62. Herbison PG, Ellis G, Hay-Smith J, Moore K. Anticholinergic drugs
for overactive bladder syndrome in adults (Cochrane Review) The Cochrane
Library. Oxford, Engl: Update Software Ltd; 2003. Issue 1.
63. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence
in women (Cochrane Review). In press.
|
Editor’s key points
• Initial evaluation of urinary incontinence (UI) includes a focused
physical examination, urine tests, and a voiding diary.
• Postvoid residual urine must be evaluated when patients have symptoms,
when physical examination reveals signs, or when there are infections
associated with incomplete voiding (eg, a feeling of never having
really emptied the bladder, distended bladder, diabetes).
• Exercises to strengthen the muscles of the pelvic floor and programs
to retrain the bladder are the nonpharmacologic interventions most
strongly supported by evidence in the scientific literature.
• Anticholinergic drugs (tolterodine, oxybutynin) are the pharmacologic
agents that have been shown to be efficacious.
Points de repère du rédacteur
• L’évaluation initiale d’un problème d’incontinence urinaire inclut
un examen physique ciblé, un examen sommaire des urines et un journal
des mictions.
• Le résidu vésical postmictionnel doit être évalué en présence
de symptômes, de signes à l’examen physique ou de pathologies associées
à une vidange vésicale incomplète (ex: sensation de ne jamais parvenir
à vider la vessie, globe vésical, diabète).
• Les exercices de renforcement des muscles pelviens et les programmes
de rééducation vésicale sont les interventions non pharmacologiques
dont l’efficacité est la plus solidement appuyée scientifiquement.
• Les anticholinergiques (toltérodine et oxybutynine) sont des agents
pharmacologiques dont l’efficacité est bien démontrée.
|
|